Leadership & Pay ·
Madrigal Pharmaceuticals adds John C. Reed to Board, grants $675K equity
MDGLMadrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals expanded its Board from eight to nine members and elected John C. Reed, M.D., Ph.D., as a Class II director effective August 11, 2026. Dr. Reed, currently Executive Vice President of Innovative Medicine at Johnson & Johnson, will serve on the Science and Technology Committee. His compensation includes a $50,000 annual cash retainer, a $10,000 committee fee, and a $675,000 equity grant split between stock options and restricted stock units with standard vesting schedules. Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH).